



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

ZAUDERER *et al.*

Appl. No. 09/818,991

Filed: March 28, 2001

For: **Methods of Producing a Library
and Methods of Selecting
Polynucleotides of Interest**

Confirmation No. 9763

Art Unit: 1639

Examiner: Ponnaluri, P.

Atty. Docket: 1821.0050004/EKS/HCC

**Reply To Restriction Requirement
And Election of Species**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated **February 25, 2003**, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention of Group I, represented by claims 1-10 and 22-109.⁰⁰⁰¹ This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

This election is made **without** traverse.

The Office Action also required an election of species. Applicants hereby provisionally elect:

(a) expression of a suicide gene product (claims 1-10, 22, 26-30, and 43-109 are readable thereon),

⁰⁰⁰¹ The Office Action stated that claims 89-109 were directed to a method of constructing a library. However, claims 89-109 depend ultimately from claim 1, and are actually directed to a method of selecting a target polynucleotide, which was placed into Group I. Thus, Group I comprises claims 1-10 and 22-109.

- (b) osteoclast progenitor cell (claims 1-10, 22-50, and 54-109 are readable thereon),
- (c) tissue culture plastic (claims 1-10 and 22-109 are readable thereon),
- (d) tissue culture plate (claims 1-10 and 22-109 are readable thereon),
- (e) cDNA library (claims 1-10 and 22-109 are readable thereon),
- (f) a target polynucleotide that directly regulates osteoclast differentiation (claims 1-10, 22-50, and 59-109 are readable thereon),
- (g) a suicide gene that encodes the Diphtheria toxin A subunit (claims 1-10, 22, 26-30, and 43-109 are readable thereon),
- (h) tissue-restricted promoter (claims 1-10, 22-50, and 54-109 are readable thereon),
- (i) osteoclast progenitor cell (claims 1-10, 22-50, and 54-109 are readable thereon),
- (j) poxvirus vector (claims 1-10, 22-98, and 101-109 are readable thereon),
- (k) vaccinia virus vector (claims 1-10, 22-98, and 101-109 are readable thereon),
- (l) vaccinia virus p7.5 promoter (claims 1-10, 22-86, and 88-109 are readable thereon),
- (m) vaccinia virus linear genome (claims 1-10, 22-98, and 101-109 are readable thereon),
- (n) fowlpoxvirus as helper virus (claims 1-10, 22-105, and 107-109 are readable thereon), and
- (o) vaccinia virus p7.5 transfer plasmid promoter (claims 1-10, 22-86, and 88-109 are readable thereon).

Claims that read on the species described in (q) and (r) of the Office Action were placed in Groups II, VI, VII, and VIII, which have not been elected herein. Thus, Applicants have not elected a species corresponding to those in (q) and (r).

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: May 27, 2003
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

::ODMA\MHODMA\SKGF_DC1;127708;2